Reata Pharmaceuticals shares are trading lower following circulation of an FDA briefing document in which the FDA expressed concern over bardoxolone data.

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.